ICU Medical (NASDAQ:ICUI) & Delcath Systems (NASDAQ:DCTH) Head-To-Head Review

ICU Medical (NASDAQ:ICUI) and Delcath Systems (OTCMKTS:DCTH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.


This table compares ICU Medical and Delcath Systems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ICU Medical 3.56% 12.41% 9.99%
Delcath Systems -1,326.61% N/A -428.01%

Analyst Ratings

This is a breakdown of current ratings for ICU Medical and Delcath Systems, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ICU Medical 0 0 1 0 3.00
Delcath Systems 0 0 0 0 N/A

ICU Medical presently has a consensus price target of $185.00, suggesting a potential upside of 13.64%. Given ICU Medical’s higher possible upside, equities research analysts clearly believe ICU Medical is more favorable than Delcath Systems.

Earnings and Valuation

This table compares ICU Medical and Delcath Systems’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ICU Medical $1.40 billion 2.40 $28.79 million $7.71 21.12
Delcath Systems $3.41 million 0.57 -$19.22 million N/A N/A

ICU Medical has higher revenue and earnings than Delcath Systems.

Institutional and Insider Ownership

94.0% of ICU Medical shares are held by institutional investors. 11.4% of ICU Medical shares are held by company insiders. Comparatively, 4.2% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

ICU Medical has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500.


ICU Medical beats Delcath Systems on 11 of the 11 factors compared between the two stocks.

About ICU Medical

ICU Medical, Inc. develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein. The company's infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency connectors; SwabCap disinfecting caps; Tego hemodialysis connectors; NovaCath and SuperCath peripheral intravenous (IV) catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, including sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation/urologics, such as sodium chloride irrigation, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. In addition, the company offers infusion pumps under the Plum 360 and LifeCare PCA brands; Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. Further, it provides ICU Medical Mednet, an enterprise medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with's FREE daily email newsletter.